ZURA BIO LIMITED Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
ZURA BIO LIMITED (ZURA) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of -$6.23 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2026-03-19
- ZURA BIO LIMITED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2024-12-31 was $0.00.
- ZURA BIO LIMITED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2023-12-31 was $0.00.
- ZURA BIO LIMITED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2023-09-30 was $0.00.
- ZURA BIO LIMITED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2023-06-30 was $0.00.
- ZURA BIO LIMITED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2024 was -$6.23M.
- ZURA BIO LIMITED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2023 was -$10.00M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$6.23M 10-K · filed 2026-03-19 | ||
| 2024-09-30 | -$6.23M 10-Q · filed 2024-11-07 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $0.00 derived: sum of 2 quarters · filed 2024-03-28 | $0.00 derived: sum of 3 quarters · filed 2024-03-28 | -$10.00M 10-K · filed 2024-03-28 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | -$10.00M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$10.00M 10-Q · filed 2023-08-14 | ||
| 2023-03-31 | -$10.00M 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |